Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Addition of Naproxen in Critically Ill Patients Hospitalized for COVID-19 (Enacovid)
2020-001301-23Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing Naproxen + standard of care with Standard of care alone (2 arms). Primary endpoint: 30-day all-cause mortality. Started Mar 2020; status: terminated.
02
Drugs
naproxen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001301-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001301-23.